Independent Research & Diligence Memos
Operator-grade analysis of clinical claims, evidence quality, regulatory pathway, reimbursement reality, market fit, and adoption risk — where evidence, science, regulation, and economics all have to line up before a deal makes sense.
Domains we cover: medtech & medical devices, digital health & AI tools, radiology and IR, ASC and OBL economics, graphene and advanced materials, consumer products, and adjacent fields.
Do not submit PHI or patient identifiers. This is research and analysis—not medical, legal, or financial advice. No fiduciary relationship is created by submission.
Two ways to engage
Free public briefs build the open research library. Private diligence is for investors and committees who need a confidential read with a defined timeline.
Public Brief
Submit a company, product, or technology. Tell us what you're trying to figure out. If the question is interesting and we have something useful to say, we'll write a short public brief, email you the link, and post it on our research page.
- No fee, no queue, no guarantee
- Subjects we find compelling move first
- You receive an email when it goes live
- Publicly indexed; benefits everyone evaluating the same space
Private Diligence Memo
For investors, committees, family offices, and operators who need a private read with a real timeline. Includes a 30-minute discovery call to scope the question, the memo under NDA, and a follow-up call to walk through findings.
- $2,500 — single company, focused question, 10 business day turnaround
- $3,500–$5,000 — comparison work, deep technical review, or 5-day rush
- Custom — recurring or syndicate-level engagements
- Submission triggers a discovery call before any quote or commitment
When a memo is the fastest path to clarity
A memo is for decisions where the cost of being wrong is high — capital, time, reputation, scientific credibility, or clinical risk.
- You're evaluating a medtech company or AI tool and need to know if it will actually work in real workflow
- You're assessing a device or product and want adoption blockers, evidence strength, and reimbursement reality
- You're hearing big claims (accuracy, outcomes, "game-changing") and want the evidence graded
- You're evaluating a graphene, advanced materials, or consumer product company and want a sober read on technical feasibility and commercialization
- You need a clear risk register before pilots, demos, fundraising, IC meetings, or procurement conversations
- You want to avoid expensive "build-first" or "invest-first" mistakes and confirm the real constraints
What a memo includes
Public Briefs are tighter (1–2 pages, key risks and findings). Private Diligence Memos cover the full scope below.
- Executive summary (what matters, what doesn't)
- Evidence synthesis with citations (what the data actually shows)
- Workflow / use-case fit (where adoption friction happens, what it requires)
- Regulatory and reimbursement constraints (what can break commercialization)
- Risk register and failure modes (how this fails in the real world)
- Competitive landscape snapshot (who's adjacent and who's direct)
- Decision triggers (what would change the conclusion)
Private memos can be formatted for committee distribution (clean headings, short sections, no fluff).
Common memo types
Examples of where this work tends to land. We'll write outside these too if the question is in our wheelhouse.
Radiology Workflow & AI Adoption
Practical evaluation of radiology AI claims through workflow, liability, and real-world adoption.
- Structured reporting + guideline logic (LI-RADS, BI-RADS, TI-RADS)
- PACS/RIS friction and "time-to-use" reality
- False positives/negatives and downstream cost
Med-Tech Device Evidence
Evidence strength, clinical fit, and commercialization constraints for devices in IR/OR/procedural medicine.
- Evidence quality and endpoint relevance
- Training burden and procedure time impact
- Reimbursement and coding considerations
Graphene & Advanced Materials
Sober assessment of graphene and materials claims, manufacturing realities, and credible use cases.
- What "graphene" actually means in this product (flake vs film vs composite)
- Manufacturing scalability and QC bottlenecks
- Where value is real and where it's marketing
Consumer Products & Brand Claims
Independent read on consumer-facing claims, ingredient or technology plausibility, and competitive defensibility.
- Scientific or clinical claims grading
- Differentiation vs incumbents
- Regulatory exposure (FTC, FDA OTC, supplement claims)
Healthcare Automation / RAG Systems
When a team wants an "AI copilot," this clarifies what's feasible, what data is needed, and what to build first.
- RAG viability and knowledge source quality
- Security boundaries and no-PHI starting points
- Human-in-the-loop design and failure handling
ASC / OBL & Procedural Economics
Unit economics, case mix, payer reality, and operational viability for ambulatory and office-based procedural environments.
- Reimbursement modeling by procedure mix
- Operational cost structure and break-even
- Investor / partnership structure considerations
Submit a Public Brief Request
Tell us what you'd like evaluated and what you're trying to figure out. If we take it on, we'll email you the link before it posts on /research. If we don't, your request stays in our file for future reference.
Request Private Diligence
Submission triggers an outreach within 2 business days to schedule a 30-minute discovery call. We confirm scope and quote before any work begins.
Process
You submit through the form above (Public Brief or Private Diligence)
For private requests: a 30-minute discovery call to scope the question and confirm fit
For brief requests: we review and decide whether to produce — interesting subjects move first
You receive a structured memo with sources and a clear conclusion
Optional follow-up call to walk through findings (included with private engagements)
FAQ
Yes. The brief itself is free if we choose to write it. The trade is that it gets posted publicly on /research, where it benefits everyone evaluating the same space (including future readers). We don't commit to producing a brief on every submission — we choose based on whether the topic is novel, broadly useful, and a fit for our expertise.
Confidential, deeper (10–15 pages), under NDA, with a defined turnaround and a discovery call to scope the question. Best for investors, committees, family offices, and operators making real capital or partnership decisions.
No. We provide research and analysis to clarify evidence, constraints, and risk. Memos are not investment, legal, or regulatory advice, and no fiduciary relationship is created by submission.
No. Companies cannot pay to be evaluated favorably or pay to suppress a memo. The Private Diligence fee covers the buyer's analysis — not the company's reputation management.
No. Do not submit PHI or patient identifiers through intake forms. If sensitive technical materials are involved, mention it in the submission and we'll handle them under NDA.
That's fine. We can still assess what's credible, what's missing, and what would be required to validate.
Yes. If the memo supports it, we can scope a build via a Spec Sprint and route you to the right path.
Get a clearer read
If a claim matters, don't guess. Submit a Public Brief or request Private Diligence and we'll take it from there.
Research and analysis only. Not medical, legal, or financial advice. No fiduciary relationship is created by submission.
Written and reviewed by Pouyan Golshani, MD, Interventional Radiologist — Last updated April 7, 2026